The diversion and misuse of pharmaceutical stimulants: What do we know and why should we care?

Addiction

Volumn 107, Issue 3, 2012, Pages 467-477

  Kaye, Sharlene ^a   Darke, Shane ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

ADHD; Attention deficit hyperactive disorder; Diversion; Misuse; Pharmaceutical; Stimulants

Indexed keywords

CENTRAL STIMULANT AGENT; STREET DRUG;

ADDICTION; ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER; HEALTH SERVICE; HUMAN; MOTIVATION; PRESCRIPTION; PREVALENCE; REVIEW; STATISTICS;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG PRESCRIPTIONS; HEALTH SERVICES MISUSE; HUMANS; MOTIVATION; PREVALENCE; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84856702263     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2011.03720.x     Document Type: Article

References (131)

1. Faraone S. V., Sergeant J., Gillberg C., Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003; 2: 104-13.
2. Polanczyk G., de Lima M. S., Horta B. L., Biederman J., Rohde L. A. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007; 164: 942-8.
3. Skounti M., Philalithis A., Galanakis E. Variations in prevalence of attention deficit hyperactivity disorder worldwide. Eur J Pediatr 2007; 166: 117-23.
4. Kessler R. C., Adler L., Barkley R., Biederman J., Conners C. K., Demler O. etal. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006; 163: 716-23.
5. Fayyad J., De Graaf R., Kessler R., Alonso J., Angermeyer M., Demyttenaere K. etal. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007; 190: 402-9.
6. Castle L., Aubert R. E., Verbrugge R. R., Khalid M., Epstein R. S. Trends in medication treatment for ADHD. J Atten Disord 2007; 10: 335-42.
7. Judson R., Langdon S. W. Illicit use of prescription stimulants among college students: prescription status, motives, theory of planned behaviour, knowledge and self-diagnostic tendencies. Psychol Health Med 2009; 14: 97-104.
8. Poulin C. From attention-deficit/hyperactivity disorder to medical stimulant use to the diversion of prescribed stimulants to non-medical stimulant use: connecting the dots. Addiction 2007; 102: 740-51.
9. Wilens T. E., Adler L. A., Adams J., Sgambati S., Rotrosen J., Sawtelle R. etal. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008; 47: 21-31.
10. Heal D. J., Cheetham S. C., Smith S. L. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. Neuropharmacology 2009; 57: 608-18.
11. Royal Australasian College of Physicians. Draft Australian Guidelines on Attention Deficit Hyperactivity Disorder (ADHD). Sydney: Royal Australasian College of Physicians; 2009.
12. Vetter V. L., Elia J., Erickson C., Berger S., Blum N., Uzark K. etal. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 2008; 117: 2407-23.
13. MIMS Australia Pty Ltd. MIMS Online. 2011. Available at: (accessed 12 May 2011; archived by Webcite at).
14. Nissen S. E. ADHD drugs and cardiovascular risk [see comment]. N Engl J Med 2006; 354: 1445-8.
15. Marsh L., Kay J., Payne T. Methylphenidate misuse in substance abusing adolescents. J Child Adolesc Subst Abuse 2000; 9: 1-14.
16. Williams R. J., Goodale L. A., Shay-Fiddler M. A., Gloster S. P., Chang S. Y. Methylphenidate and dextroamphetamine abuse in substance-abusing adolescents. Am J Addict 2004; 13: 381-9.
17. National Institute on Drug Abuse (NIDA). Prescription Drugs. Abuse and Addiction. 2005.
18. de la Garza R., Johanson C. E. The discriminative stimulus properties of cocaine and d-amphetamine: the effects of three routes of administration. Pharmacol, Biochem Behav 1986; 24: 765-8.
19. Kollins S. H. Abuse liability of medications used to treat attention-deficit/hyperactivity disorder (ADHD). Am J Addict 2007; 16: 35-42. quiz 43-4.
20. Spencer T. J., Biederman J., Ciccone P. E., Madras B. K., Dougherty D. D., Bonab A. A. etal. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry 2006; 163: 387-95.
21. Kollins S. H., Rush C. R., Pazzaglia P. J., Ali J. A. Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp Clin Psychopharmacol 1998; 6: 367-74.
22. Volkow N. D., Wang G. J., Fowler J. S., Gatley S. J., Logan J., Ding Y. S. etal. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998; 155: 1325-31.
23. Connor D. F., Steingard R. J. New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential. CNS Drugs 2004; 18: 1011-30.
24. Khan I. Convention on psychotropic substances, 1971: the role and responsibilities of the World Health Organization. Prog Neuropsychopharmacol 1979; 3: 11-4.
25. Kollins S. H. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. J Clin Psychiatry 2003; 64: 14-8.
26. Kroutil L. A., Van Brunt D. L., Herman-Stahl M. A., Heller D. C., Bray R. M., Penne M. A. Nonmedical use of prescription stimulants in the United States. Drug Alcohol Depend 2006; 84: 135-43.
27. Wilens T. E., Gignac M., Swezey A., Monuteaux M. C., Biederman J. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 2006; 45: 408-14.
28. Fischer B., Bibby M., Bouchard M. The global diversion of pharmaceutical drugs non-medical use and diversion of psychotropic prescription drugs in North America: a review of sourcing routes and control measures. Addiction 2010; 105: 2062-70.
29. Riggs P. Non-medical use and abuse of commonly prescribed medications. Curr Med Res Opin 2008; 24: 869-77.
30. Blanco C., Alderson D., Ogburn E., Grant B. F., Nunes E. V., Hatzenbuehler M. L. etal. Changes in the prevalence of non-medical prescription drug use and drug use disorders in the United States: 1991-1992 and 2001-2002. Drug Alcohol Depend 2007; 90: 252-60.
31. Fountain J., Strang J., Gossop M., Farrell M., Griffiths P. Diversion of prescribed drugs by drug users in treatment: analysis of the UK market and new data from London. Addiction 2000; 95: 393-406.
32. Carise D., Dugosh K. L., McLellan A. T., Camilleri A., Woody G. E., Lynch K. G. Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry 2007; 164: 1750-6.
33. Cicero T. J., Inciardi J. A., Munoz A. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain 2005; 6: 662-72.
34. Paulozzi L. J. Opioid analgesic involvement in drug abuse deaths in American metropolitan areas. Am J Public Health 2006; 96: 1755-7.
35. Paulozzi L. J., Ryan G. W. Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med 2006; 31: 506-11.
36. Faber A., de Jong-van den Berg L. T. W., van den Berg P. B., Tobi H. Psychotropic co-medication among stimulant-treated children in the Netherlands. J Child Adolesc Psychopharmacol 2005; 15: 38-43.
37. Berbatis C. G., Sunderland V. B., Bulsara M. Licit psychostimulant consumption in Australia, 1984-2000: international and jurisdictional comparison. Med J Aust 2002; 177: 539-43.
38. Scheffler R. M., Hinshaw S. P., Modrek S., Levine P. The global market for ADHD medications. Health Aff 2007; 26: 450-7.
39. International Narcotics Control Board. Report of the International Narcotics Control Board for 2009. New York: United Nations; 2010.
40. Safer D. J., Krager J. M. A survey of medication treatment for hyperactive/inattentive students. JAMA 1988; 260: 2256-8.
41. Zito J. M., Safer D. J., dosReis S., Gardner J. F., Boles M., Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 2000; 283: 1025-30.
42. Schirm E., Tobi H., Zito J. M., de Jong-van den Berg L. T. Psychotropic medication in children: a study from the Netherlands. Pediatrics 2001; 108: E25.
43. Janols L.-O., Liliemark J., Klintberg K., von Knorring A.-L. Central stimulants in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents. A naturalistic study of the prescription in Sweden, 1977-2007. Nord J Psychiatry 2009; 63: 508-16.
44. Gumy C., Huissoud T., Dubois-Arber F. Prevalence of methylphenidate prescription among school-aged children in a Swiss population: increase in the number of prescriptions in the Swiss Canton of Vaud, from 2002 to 2005, and changes in patient demographics. J Atten Disord 2010; 14: 267-72.
45. LeFever G. B., Arcona A. P., Antonuccio D. O. ADHD among American schoolchildren: evidence of overdiagnosis and overuse of medication. Sci Rev Ment Health Pract 2003; 2: 49-60.
46. Sciutto M. J., Eisenberg M. Evaluating the evidence for and against the overdiagnosis of ADHD. J Atten Disord 2007; 11: 106-13.
47. Vendruscolo L. F., Izidio G. S., Takahashi R. N., Ramos A. Chronic methylphenidate treatment during adolescence increases anxiety-related behaviors and ethanol drinking in adult spontaneously hypertensive rats. Behav Pharmacol 2008; 19: 21-7.
48. Miller A. R., Lalonde C. E., McGrail K. M., Armstrong R. W. Prescription of methylphenidate to children and youth, 1990-1996. Can Med Assoc J 2001; 165: 1489-94.
49. Robison L. M., Sclar D. A., Skaer T. L., Galin R. S. National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990-1995. Clin Pediatr 1999; 38: 209-17.
50. Hollingworth S. A., Nissen L. M., Stathis S. S., Siskind D. J., Varghese J. M. N., Scott J. G. Australian national trends in stimulant dispensing: 2002-2009. Aust NZ J Psychiatry 2011; 45: 332-6.
51. Prosser B., Reid R. Changes in use of psychostimulant medication for ADHD in South Australia (1990-2006). Aust N Z J Psychiatry 2009; 43: 340-7.
52. Knellwolf A.-L., Deligne J., Chiarotti F., Auleley G.-R., Palmieri S., Boisgard C. B. etal. Prevalence and patterns of methylphenidate use in French children and adolescents. Eur J Clin Pharmacol 2008; 64: 311-7.
53. Vinker S., Vinker R., Elhayany A. Prevalence of methylphenidate use among Israeli children: 1998-2004. Clin Drug Invest 2006; 26: 161-7.
54. Schepis T. S., Marlowe D. B., Forman R. F. The availability and portrayal of stimulants over the internet. J Adolesc Health 2008; 42: 458-65.
55. Wu L.-T., Pilowsky D. J., Schlenger W. E., Galvin D. M. Misuse of methamphetamine and prescription stimulants among youths and young adults in the community. Drug Alcohol Depend 2007; 89: 195-205.
56. Substance Abuse and Mental Health Services Administration (SAMHSA) and Office of Applied Studies. Results from the 2003 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD.: SAMHSA; 2004.
57. Substance Abuse and Mental Health Services Administration (SAMHSA) and Office of Applied Studies. Results from the 2004 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD.:SAMHSA; 2005.
58. Substance Abuse and Mental Health Services Administration (SAMHSA) and Office of Applied Studies. Results from the 2005 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD.:SAMHSA; 2006.
59. Substance Abuse and Mental Health Services Administration (SAMHSA) and Office of Applied Studies. Results from the 2006 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD.: SAMHSA; 2007.
60. Substance Abuse and Mental Health Services Administration (SAMHSA) and Office of Applied Studies. Results from the 2007 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD.:SAMHSA; 2008.
61. Substance Abuse and Mental Health Services Administration (SAMHSA) and Office of Applied Studies. Results from the 2008 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD.: SAMHSA; 2009.
62. Substance Abuse and Mental Health Services Administration (SAMHSA) and Office of Applied Studies. Results from the 2009 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD: SAMHSA; 2010.
63. Kessler R. C., McGonagle K. A., Zhao S., Nelson C. B., Hughes M., Eshleman S. etal. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8-19.
64. Australian Institute of Health and Welfare (AIHW). 2004 National Drug Strategy Household Survey: Detailed Findings. Canberra: AIHW; 2005.
65. Australian Institute of Health and Welfare (AIHW). 2007 National Drug Strategy Household Survey: Detailed Findings. Canberra: AIHW; 2008.
66. Grant B. F., Stinson F. S., Dawson D. A., Chou S. P., Dufour M. C., Compton W. etal. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004; 61: 807-16.
67. Tominaga M., Kawakami N., Ono Y., Nakane Y., Nakamura Y., Tachimori H. etal. Prevalence and correlates of illicit and non-medical use of psychotropic drugs in Japan: findings from the World Mental Health Japan Survey 2002-2004. Soc Psychiatry Psychiatr Epidemiol 2009; 44: 777-83.
68. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2010. New York: UNODC; 2010.
69. Novak S. P., Kroutil L. A., Williams R. L., Van Brunt D. L. The nonmedical use of prescription ADHD medications: results from a national Internet panel. Subst Abuse Treat Prev Policy 2007; 2: 32. Available at (archived by Webcite at).
70. Currie C. L., Schopflocher D. P., Wild T. C. Prevalence and correlates of 12-month prescription drug misuse in Alberta. Can J Psychiatry 2011; 56: 27-34.
71. Johnston L. D., O'Malley P. M., Bachman J. G., Schulenberg J. E. Monitoring the Future National Survey Results on Drug Use, 1975-2009. Volume II: College Students and Adults Ages 19-50. Bethesda, MD: National Institute on Drug Abuse; 2010.
72. Bogle K. E., Smith B. H. Illicit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences. Curr Drug Abuse Rev 2009; 2: 157-76.
73. Johnston L. D., O'Malley P. M., Bachman J. G., Schulenberg J. E. Monitoring the Future National Survey Results on Drug Use, 1975-2009. Vol. I: Secondary School Students. Bethesda, MD: National Institute on Drug Abuse; 2010.
74. Boyd C. J., McCabe S. E., Cranford J. A., Young A., Boyd C. J., McCabe S. E. etal. Prescription drug abuse and diversion among adolescents in a southeast Michigan school district. Arch Pediatr Adolesc Med 2007; 161: 276-81.
75. Franke A. G., Bonertz C., Christmann M., Huss M., Fellgiebel A., Hildt E. etal. Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry 2011; 44: 60-6.
76. Hibell B., Guttormsson U., Ahlström S., Balakireva O., Bjarnason T., Kokkevi A. etal. The 2007 ESPAD Report. Substance Use Among Students in 35 European Countries. Stockholm: The Swedish Council for Information on Alcohol and Other Drugs (CAN); 2009.
77. White V., Smith G. Australian Secondary School Students' Use of Tobacco, Alcohol, and over-the-Counter and Illicit Substances in 2008. Melbourne: Centre for Behavioural Research in Cancer; 2009.
78. Miller J., Lang A. ASSAD Drug Report 2005. Perth: WA Drug and Alcohol Office; 2007.
79. Haynes R., Kalic R., Griffiths P., McGregor C., Gunnell A. P. Australian School Student Alcohol and Drug Survey: Illicit Drug Report 2008-Western Australian Results. Perth: Drug and Alcohol Office; 2010.
80. Lord S., Downs G., Furtaw P., Chaudhuri A., Silverstein A., Gammaitoni A. etal. Nonmedical use of prescription opioids and stimulants among student pharmacists. J Am Pharm Assoc (Washington DC) 2009; 49: 519-28.
81. Sharp J. T., Rosen L. A. Recreational stimulant use among college students. J Subst Use 2007; 12: 71-82.
82. McCabe S. E., Teter C. J. Drug use related problems among nonmedical users of prescription stimulants: a web-based survey of college students from a Midwestern university. Drug Alcohol Depend 2007; 91: 69-76.
83. Advokat C. D., Guidry D., Martino L. Licit and illicit use of medications for attention-deficit hyperactivity disorder in undergraduate college students. J Am Coll Health 2008; 56: 601-6.
84. Arria A. M., Caldeira K. M., O'Grady K. E., Vincent K. B., Johnson E. P., Wish E. D. Nonmedical use of prescription stimulants among college students: associations with attention-deficit-hyperactivity disorder and polydrug use. Pharmacotherapy 2008; 28: 156-69.
85. Dupont R. L., Coleman J. J., Bucher R. H., Wilford B. B. Characteristics and motives of college students who engage in nonmedical use of methylphenidate. Am J Addict 2008; 17: 167-71.
86. Habibzadeh A., Alizadeh M., Malek A., Maghbooli L., Shoja M. M., Ghabili K. Illicit methylphenidate use among Iranian medical students: prevalence and knowledge. Drug Des Dev Ther 2011; 5: 71-6.
87. DeSantis A. D., Webb E. M., Noar S. M. Illicit use of prescription ADHD medications on a college campus: a multimethodological approach. J Am Coll Health 2008; 57: 315-24.
88. Benotsch E. G., Koester S., Luckman D., Martin A. M., Cejka A. Non-medical use of prescription drugs and sexual risk behavior in young adults. Addict Behav 2011; 36: 152-5.
89. Sussman S., Pentz M. A., Spruijt-Metz D., Miller T. Misuse of 'study drugs:' prevalence, consequences, and implications for policy. Subst Abuse Treat, Prev, Policy 2006; 1: 15. Available at (archived by Webcite at).
90. Substance Abuse and Mental Health Services Administration (SAMHSA) and Office of Applied Studies. The NSDUH Report: Nonmedical Use of Adderall® among Full-Time College Students. Rockville, MD: SAMHSA; 2009.
91. Weyandt L. L., Janusis G., Wilson K. G., Verdi G., Paquin G., Lopes J. etal. Nonmedical prescription stimulant use among a sample of college students: relationship with psychological variables. J Atten Disord 2009; 13: 284-96.
92. Low K. G., Gendaszek A. E. Illicit use of psychostimulants among college students: a preliminary study. Psychol Health Med 2002; 7: 283-7.
93. Musser C. J., Ahmann P. A., Theye F. W., Mundt P., Broste S. K., Mueller-Rizner N. Stimulant use and the potential for abuse in Wisconsin as reported by school administrators and longitudinally followed children. J Dev Behav Pediatr 1998; 19: 187-92.
94. Darredeau C., Barrett S. P., Jardin B., Pihl R. O., Darredeau C., Barrett S. P. etal. Patterns and predictors of medication compliance, diversion, and misuse in adult prescribed methylphenidate users. Hum Psychopharmacol 2007; 22: 529-36.
95. Bright G. M. Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey. Medscape J Med 2008; 10: 111.
96. Rabiner D. L., Anastopoulos A. D., Costello E. J., Hoyle R. H., McCabe S. E., Swartzwelder H. S. The misuse and diversion of prescribed ADHD medications by college students. J Atten Disord 2009; 13: 144-53.
97. Parran T. V., Jr, Jasinski D. R. Intravenous methylphenidate abuse. Prototype for prescription drug abuse. Arch Intern Med 1991; 151: 781-3.
98. Raskind M., Bradford T. Methylphenidate (Ritalin) abuse and methadone maintenance. Dis Nerv Syst 1975; 36: 9-12.
99. Haglund R. M., Howerton L. L. Ritalin: consequences of abuse in a clinical population. Int J Addict 1982; 17: 349-56.
100. Silins E., Copeland J., Dillon P. Patterns and harms of pharmaceutical drug use among ecstasy users in Australia. Adicciones 2009; 21: 347-62.
101. Stafford J., Burns L. Australian Drug Trends 2009. Findings from the Illicit Drug Reporting System (IDRS). Sydney: National Drug and Alcohol Research Centre; 2010.
102. Sindicich N., Burns L. Australian Trends in Ecstasy and Related Drug Markets 2010. Findings from the Ecstasy and Related Drugs Reporting System (EDRS). Sydney: National Drug and Alcohol Research Centre; 2010.
103. Poulin C. Medical and nonmedical stimulant use among adolescents: from sanctioned to unsanctioned use [see comment]. Can Med Assoc J 2001; 165: 1039-44.
104. McCabe S. E., Teter C. J., Boyd C. J., McCabe S. E., Teter C. J., Boyd C. J. The use, misuse and diversion of prescription stimulants among middle and high school students. Subst Use Misuse 2004; 39: 1095-116.
105. Upadhyaya H. P., Rose K., Wang W., O'Rourke K., Sullivan B., Deas D. etal. Attention-deficit/hyperactivity disorder, medication treatment, and substance use patterns among adolescents and young adults. J Child Adolesc Psychopharmacol 2005; 15: 799-809.
106. Garnier L. M., Arria A. M., Caldeira K. M., Vincent K. B., O'Grady K. E., Wish E. D. Sharing and selling of prescription medications in a college student sample. J Clin Psychiatry 2010; 71: 262-9.
107. Barrett S. P., Darredeau C., Bordy L. E., Pihl R. O. Characteristics of methylphenidate misuse in a university student sample. Can J Psychiatry 2005; 50: 457-61.
108. McCabe S. E., Teter C. J., Boyd C. J. Medical use, illicit use and diversion of prescription stimulant medication. J Psychoact Drugs 2006; 38: 43-56.
109. Kaloyanides K. B., McCabe S. E., Cranford J. A., Teter C. J. Prevalence of illicit use and abuse of prescription stimulants, alcohol, and other drugs among college students: relationship with age at initiation of prescription stimulants. Pharmacotherapy 2007; 27: 666-74.
110. Herman-Stahl M. A., Krebs C. P., Kroutil L. A., Heller D. C. Risk and protective factors for methamphetamine use and nonmedical use of prescription stimulants among young adults aged 18 to 25. Addict Behav 2007; 32: 1003-15.
111. Teter C. J., McCabe S. E., Boyd C. J., Guthrie S. K. Illicit methylphenidate use in an undergraduate student sample: prevalence and risk factors. Pharmacotherapy 2003; 23: 609-17.
112. Jardin B., Looby A., Earleywine M. Characteristics of college students with attention-deficit hyperactivity disorder symptoms who misuse their medications. J Am Coll Health 2011; 59: 373-7.
113. Hall K. M., Irwin M. M., Bowman K. A., Frankenberger W., Jewett D. C. Illicit use of prescribed stimulant medication among college students. J Am Coll Health 2005; 53: 167-74.
114. Faraone S. V., Wilens T. E. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion. J Clin Psychiatry 2007; 68: 15-22.
115. White B. P., Becker-Blease K. A., Grace-Bishop K. Stimulant medication use, misuse, and abuse in an undergraduate and graduate student sample. J Am Coll Health 2006; 54: 261-8.
116. Setlik J., Bond G. R., Ho M. Adolescent prescription ADHD medication abuse is rising along with prescriptions for these medications. Pediatrics 2009; 124: 875-80.
117. Bruggisser M., Ceschi A., Bodmer M., Wilks M. F., Kupferschmidt H., Liechti M. E. Retrospective analysis of stimulant abuse cases reported to the Swiss Toxicological Information Centre during 1997-2009. Swiss Med Wkly 2010; 140: w13115.
118. Coetzee M., Kaminer Y., Morales A. Megadose intranasal methylphenidate (Ritalin) abuse in adult attention deficit hyperactivity disorder. Subst Abus 2002; 23: 165-9.
119. Crutchley A., Temlett J. A. Methylphenidate (Ritalin) use and abuse. S Afr Med J 1999; 89: 1076-9.
120. Simoni-Wastila L., Strickler G. Risk factors associated with problem use of prescription drugs. Am J Public Health 2004; 94: 266-8.
121. Kaye S., McKetin R., Duflou J., Darke S. Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction 2007; 102: 1204-11.
122. Karch S. B. Karch's Pathology of Drug Abuse. Boca Raton: CRC Press; 2002.
123. Darke S., Kaye S., Duflou J. Cocaine-related fatalities in New South Wales, Australia 1993-2002. Drug Alcohol Depend 2005; 77: 107-14.
124. Karch S. B., Stephens B. G., Ho C. H. Methamphetamine-related deaths in San Francisco: demographic, pathologic, and toxicological profiles. J Forensic Sci 1999; 44: 359-68.
125. Logan B., Fligner C. L., Haddix T. Cause and manner of death in fatalities involving methamphetamine. J Forensic Sci 1998; 43: 28-34.
126. Klein-Schwartz W. Abuse and toxicity of methylphenidate. Curr Opin Pediatr 2002; 14: 219-23.
127. Massello W., 3rd, Carpenter D. A. A fatality due to the intranasal abuse of methylphenidate (Ritalin). J Forensic Sci 1999; 44: 220-1.
128. Levine B., Caplan Y. H., Kauffman G. Fatality resulting from methylphenidate overdose. J Anal Toxicol 1986; 10: 209-10.
129. Darke S., Degenhardt L., Mattick R. Mortality Amongst Illicit Drug Users. Cambridge: Cambridge University Press; 2007.
130. Welder A. A. A primary culture system of postnatal rat heart cells for the study of cocaine and methamphetamine toxicity. Toxicol Lett 1992; 60: 183-96.
131. Kaye S., Darke S., Duflou J., McKetin R. Methamphetamine-related fatalities in Australia: demographics, circumstances, toxicology and major organ pathology. Addiction 2008; 103: 1353-60.